Replies to post #244847 on Biotech Values

[DewDiligence]

CYTH closes_acquisition_of AMTI for ~$0.26/sh* in_stock—a 25% premium to AMTI’s share price prior to the 9/21/23 announcement of the deal:

https://www.businesswire.com/news/home/20231227151063/en

AMTI has essentially been a shell company since its clinical failure one year ago (#msg-170779298).

*Based on CYTH’s latest price in today’s AH session.